Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Combinations of Bevacizumab With Cancer Immunotherapy.

Chen DS, Hurwitz H.

Cancer J. 2018 Jul/Aug;24(4):193-204. doi: 10.1097/PPO.0000000000000327.

PMID:
30119083
2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2015 Dec;4(6):728-42. doi: 10.3978/j.issn.2218-6751.2015.12.04. Review.

4.

The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY, Go H.

Oncologist. 2015 Nov;20(11):1253-60. doi: 10.1634/theoncologist.2015-0151. Epub 2015 Sep 30.

5.

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.

Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN.

J Immunother Cancer. 2013 Aug 29;1:15. doi: 10.1186/2051-1426-1-15. eCollection 2013.

6.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.

Läubli H, Müller P, D'Amico L, Buchi M, Kashyap AS, Zippelius A.

Cancer Immunol Immunother. 2018 May;67(5):815-824. doi: 10.1007/s00262-018-2136-x. Epub 2018 Feb 27.

PMID:
29487979
7.

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.

Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW.

Front Oncol. 2018 Mar 22;8:71. doi: 10.3389/fonc.2018.00071. eCollection 2018.

8.

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.

Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M.

Cell Rep. 2017 May 30;19(9):1874-1887. doi: 10.1016/j.celrep.2017.05.015.

9.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, Esandrio J, Xu H, Ogurtsova A, Cornish T, Lipson EJ, Topalian SL, Engels EA, Taube JM.

JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.

10.

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z.

Oncoimmunology. 2014 Dec 13;3(9):e955331. eCollection 2014 Oct.

11.

Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.

Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M.

Cancer Sci. 2018 Jul;109(7):2119-2129. doi: 10.1111/cas.13649. Epub 2018 Jun 16.

12.

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Ramjiawan RR, Griffioen AW, Duda DG.

Angiogenesis. 2017 May;20(2):185-204. doi: 10.1007/s10456-017-9552-y. Epub 2017 Mar 30. Review.

13.

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.

Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S.

Int J Oncol. 2017 Jan;50(1):41-48. doi: 10.3892/ijo.2016.3785. Epub 2016 Dec 2.

14.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
15.

Rational combination of immunotherapy for triple negative breast cancer treatment.

Li CW, Lim SO, Hsu JL, Hung MC.

Chin Clin Oncol. 2017 Oct;6(5):54. doi: :10.21037/cco.2017.08.04. Review.

16.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

17.

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).

Kim JM, Chen DS.

Ann Oncol. 2016 Aug;27(8):1492-504. doi: 10.1093/annonc/mdw217. Epub 2016 May 20. Review.

PMID:
27207108
18.

Immunomodulatory Activity of VEGF in Cancer.

Lapeyre-Prost A, Terme M, Pernot S, Pointet AL, Voron T, Tartour E, Taieb J.

Int Rev Cell Mol Biol. 2017;330:295-342. doi: 10.1016/bs.ircmb.2016.09.007. Epub 2016 Dec 26. Review.

PMID:
28215534
19.

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.

Song M, Chen X, Wang L, Zhang Y.

Chin J Cancer Res. 2018 Apr;30(2):157-172. doi: 10.21147/j.issn.1000-9604.2018.02.01.

20.

Emerging drugs targeting PD-1 and PD-L1: reality or hope?

Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.

Expert Opin Emerg Drugs. 2014 Dec;19(4):557-69. doi: 10.1517/14728214.2014.964682. Epub 2014 Sep 25. Review.

PMID:
25253438

Supplemental Content

Support Center